Background & Objectives

People living with Type 1 Diabetes (T1D) require daily injections of insulin to mimic the function of the pancreas and compensate the lack of insulin production.

Despite advances in insulin delivery systems and blood glucose monitoring, managing glycaemia as closely as is achieved through the body’s normal response to lower the risk of developing complications is difficult.

One solution is to develop insulin-producing cells to remove the need for injections.

Islet transplantations already exist but are currently only available to those who experience severe issues with diabetes management; are constrained by the lack of donors; and require immunosuppression, leaving people vulnerable to infection.

This project aims to build and implement a new and innovative programme for the production and marketing of human pluripotent stem cell (hPSC)-derived advanced therapy medicinal products (ATMPs) for the treatment of people living with T1D.

IDF Europe’s role

✓ Ensure the perspectives of people living with diabetes are represented throughout the project
✓ Raise awareness of diabetes and advanced therapies.
✓ Disseminate and communicate around the project and its outcomes.

Deliverables

• A first generation cell-therapy product consisting of insulin-producing beta cells derived from human pluripotent stem cells.
• Next generation cell-therapy by engineering islet-like clusters from human pluripotent stem cells in the lab.
• A pipeline to people living with T1D consisting of a Good Manufacturing Procedure (GMP) compliant manufacturing step; a pre-clinical testing step and a commercialisation step.

Expected Impact

Over the long term, new scalable sources of islets for transplantation, leading to a reduced burden and improved quality of life for people living with diabetes.

Project partners

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 874839 ISLET

www.idf-europe.org